Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2332-2341

  Chon, Young Eun ^a,b   Choi, Gi Hong ^a   Lee, Myoung Ha ^a,b   Kim, Seung Up ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b   Kim, Kyung Sik ^a   Choi, Jin Sub ^a   Han, Kwang Hyub ^a,b   Chon, Chae Yoon ^a,b   Park, Jun Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

fetoprotein; curative resection; des carboxy prothrombin; hepatocelullar carcinoma; recurrence

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RECURRENCE;

EID: 84867081369     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27507     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Nobuoka D, Kato Y, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T, Nakatsura T,. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 2010; 24: 521-8.
3. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM,. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-35.
4. Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C, Ikeda M, Ueno H, Okusaka T, Arai Y, Takayasu K,. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 2337-47.
5. Choi GH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Lee WJ, Han KH, Chon CY, Kim BR,. The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2009; 24: 391-8.
6. Kim BK, Park JY, Kim DY, Kim JK, Kim KS, Choi JS, Moon BS, Han KH, Chon CY, Moon YM, Ahn SH,. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008; 28: 393-401.
7. Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Park YN, Park JY, Kim DY, Han K, Chon CY, et al. Outcome after curative resection for a huge (>or = 10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 2009; 198: 693-701.
8. Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe T, Honjo I,. Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 1982; 49: 354-60.
9. Peng S, Chen WJ, Lai P, Jeng Y, Sheu J, Hsu H,. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112: 44-50.
10. Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, Lee DY, Seong J, Han KH, Chon CY, Park JY,. Early on-treatment predictions of clinical outcomes using AFP and DCP responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 28: 1440-746.
11. Collier J, Sherman M,. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.
12. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S,. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-6.
13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rods J,. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
14. Uehara S, Gotoh K, Handa H, Honjo K, Hirayama A,. Process of carboxylation of glutamic acid residues in the gla domain of human des-gamma-carboxyprothrombin. Clin Chim Acta 1999; 289: 33-44.
15. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T,. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 1991; 36: 1787-92.
16. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H,. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77: 1781-6.
17. Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N,. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16: 2795-804.
18. Nanashima A, Sumida Y, Tobinaga S, Shibata K, Shindo H, Obatake M, Shibasaki S, Ide N, Nagayasu T,. Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis. HPB 2006; 8: 137-41.
19. Edge SB, Carducc iMA, Compton CC,. AJCC cancer staging manual, 7th edn., 2009. 237 p.
20. Edmondson HA, Steiner PE,. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
21. Carr BI, Kanke F, Wise M, Satomura S,. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52: 776-82.
22. Cucchetti A, Piscaglia F, Caturelli E, Benvegn L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L, Pinna AD,. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413-22.
23. Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N,. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int 2011; 31: 22-35.
24. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S, Omata M,. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
25. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T,. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006; 41: 1214-9.
26. Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan L, Ohnishi S, Makuuchi M,. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003; 22: 969-75.
27. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M,. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-7.
28. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J,. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
29. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K,. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62: 1.
30. Hu K, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T,. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99: 860-5.
31. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, Chung H, Kudo M, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008; 49: 223-32.
32. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A, Shiratori Y,. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005; 280: 6409-15.
33. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, Sakaguchi K, Shiratori Y,. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007; 282: 8741-8.
34. Wang S, Cheng Y, Cui S, Zhong JL, Ward SG, Sun L, Chen M, Kokudo N, Tang W, Qu X,. Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 2009; 26: 469-77.
35. Ning S, Bin C, Na H, Peng S, Yi D, Xiang Hua Y, Fang Yin Z, Da Yong Z, Rong Cheng L,. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012; 39: 351-7.
36. Tada T, Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kitabatake S, Kuzuya T, Nonogaki K, Shimizu J, Yamaguchi A, et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25: 848-53.